公开(公告)号：US20190040128A1

公开(公告)日：2019-02-07

申请号：US15971250

申请日：2018-05-04

Applicant: NOVARTIS AG

Inventor： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

IPC: C07K16/28 ,  A61P9/08 ,  A61P9/12 ,  A61P9/04 ,  A61K9/00 ,  A61K39/395 ,  A61K45/06 ,  A61P9/10 ,  A61K39/00 ,  C07K14/47

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20170152313A1

公开(公告)日：2017-06-01

申请号：US15346026

申请日：2016-11-08

Applicant: NOVARTIS AG

Inventor： Kurt Alex HELDWEIN ,  Igor SPLAWSKI ,  Jennifer BROGDON ,  Joshua GOLDSTEIN ,  William DOLE ,  John TRAUGER ,  Chonghui ZHANG

IPC: C07K16/28 ,  A61K45/06 ,  A61K9/00 ,  A61K39/395

CPC classification number: C07K16/28 ,  A61K9/0019 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/4726 ,  C07K16/2851 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20220249614A1

公开(公告)日：2022-08-11

申请号：US17720555

申请日：2022-04-14

Applicant: NOVARTIS AG

Inventor： William CHUTKOW ,  John Richard Neville HADCOCK ,  Kurt Alex HELDWEIN ,  Aimee Richardson USERA

IPC: A61K38/19 ,  A61K47/54 ,  A61K47/60 ,  A61P1/16

Abstract: The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same.

公开(公告)号：US20210340205A1

公开(公告)日：2021-11-04

申请号：US17266828

申请日：2019-08-09

Applicant: NOVARTIS AG

Inventor： Jirong BAI ,  Kurt Alex HELDWEIN ,  Loren Daniel LINDSLEY

IPC: C07K14/495 ,  G01N33/68 ,  G01N33/566 ,  C07K16/22 ,  C07K16/28 ,  C07K14/71

Abstract: GFRAL extracellular domains comprising domains D2 and D3 are disclosed. The disclosure further relates to methods and compositions for screening and evaluating the activity of a GFRAL ligand, such as a GDF15 peptide, using the GFRAL extracellular domains provided herein. Also disclosed are methods and compositions for treating obesity, reducing appetite, and/or reducing body weight using the GFRAL extracellular domains provided herein.

公开(公告)号：US20190000923A1

公开(公告)日：2019-01-03

申请号：US16064054

申请日：2016-12-20

Applicant: NOVARTIS AG

Inventor： William CHUTKOW ,  John Richard Neville HADCOCK ,  Kurt Alex HELDWEIN ,  Aimee Richardson USERA

IPC: A61K38/19 ,  A61P1/16 ,  A61K47/54 ,  A61K47/60

Abstract: The disclosure relates to the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as end-stage liver disease, hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, liver cirrhosis, primary biliary cirrhosis (PBC), and hepatocellular carcinoma (HCC), by administering to a subject in need a GDF15 protein or a functional variant, mutation, fusion, or conjugate thereof, and to pharmaceutical compositions that contain the same.